Only 1 way to figure out: test it on (consenting) new patients. The drugs are generic (so cheap), and don’t have intolerable side effects. It has anecdotally worked. So it’s positive EV for patients with terminal prognosis. And yet its explained away as a curious ‘spontaneous’ remission, using your very valid objection.
This is after all my bigger claim / criticism of the status quo. My objective is to make a meta-level criticism more so than to advocate for one particular protocol as the potential cure. My claim is that a medical system that acted with urgency and that wanted to maximize patient survival odds, would have at the very least attempted to replicate the protocol in a Phase II clinical trial. Instead, it was ignored due to status quo bias. Not because it lacked a scientific justification, but because the drugs are generic.
In other words, I use the lack of a replication attempt to update in favor of systemic issues in oncology and FDA.
Only 1 way to figure out: test it on (consenting) new patients. The drugs are generic (so cheap), and don’t have intolerable side effects. It has anecdotally worked. So it’s positive EV for patients with terminal prognosis. And yet its explained away as a curious ‘spontaneous’ remission, using your very valid objection.
This is after all my bigger claim / criticism of the status quo. My objective is to make a meta-level criticism more so than to advocate for one particular protocol as the potential cure. My claim is that a medical system that acted with urgency and that wanted to maximize patient survival odds, would have at the very least attempted to replicate the protocol in a Phase II clinical trial. Instead, it was ignored due to status quo bias. Not because it lacked a scientific justification, but because the drugs are generic.
In other words, I use the lack of a replication attempt to update in favor of systemic issues in oncology and FDA.